| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
|
| March 16, 2023 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2023[JapaneseGAAP]
|
| December 14, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2022[JapaneseGAAP]
|
| September 8, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2022[Japanese GAAP]
|
| June 9, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2022[Japanese GAAP]
|
| March 10, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2022[JapaneseGAAP]
|
| December 12, 2021 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2021[JapaneseGAAP]
|
| September 9, 2021 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2021[Japanese GAAP]
|
| June 10, 2021 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2021[Japanese GAAP]
|
| March 11, 2021 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2021[Japanese GAAP]
|
